News and Events

Latest News

Stay up to date on all Relief activities.

Our team is working diligently to rapidly develop RLF-100™ for the benefit of COVID-19 patients. Here you will find latest news, upcoming events and interviews.

Corporate News

Archive

Relief Reports 2020 Financial Results and Provides Business Update

15 April 2021
Relief Engages Jan-Jaap Scherpbier of Sonsbeek Pharma Consultancy B.V. as Manufacturing and Supply Chain Consultant

07 April 2021
Relief Reports that NeuroRx has Announced that Aviptadil has been Selected for Inclusion in NIH-Sponsored Global Clinical Trial which Includes Aviptadil and Remdesivir

07 April 2021
Relief Confirms Release of 60-Day Findings from Phase 2b/3 Clinical Trial of Intravenous RLF-100™ (aviptadil)

30 March 2021
Relief and Acer Therapeutics Sign Collaboration and License Agreement for Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease

22 March 2021
Relief Reports that NeuroRx has Announced Feasibility Collaboration with TFF Pharmaceuticals

15 March 2021
Relief Announces CHF 10 Million Private Placement

12 March 2021
Relief Increases Issued Share Capital with Creation of Treasury Shares

08 March 2021
Relief Reports that NeuroRx Announced that RLF-100™ (Aviptadil) has Successfully Demonstrated Ten-Day Accelerated Recovery from Respiratory Failure among Critically Ill Patients with Covid-19 Treated with High Flow Nasal Oxygen at 28 Day Interim Endpoint

24 February 2021
Relief Confirms Release of Preliminary Findings from Phase 2b/3 Trial of Intravenous RLF-100™ (aviptadil)

10 February 2021

Scientific Publications

Media Contact

For media inquires contact:

MC Services AG
Anne Hennecke / Brittney Sojeva
Mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel.: +49 (0) 211-529-252-14

Company

Pipeline

Investor Relations

News and Events

Privacy Policy

Disclaimer

Imprint

© relief therapeutics 2020